GHK-Cu: The Copper Peptide Your Body Makes Less of Every Year — and Why That Might Matter More Than You Think

The short version

GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys bound to copper) found in your blood plasma. At age 20, you have ~200 ng/mL. By 60, that drops to ~80 ng/mL — a 60% decline.
It modulates expression of over 4,000 human genes — roughly 31% of the genome — shifting patterns toward tissue repair, antioxidant defense, and anti-inflammation.
In head-to-head clinical trials, topical GHK-Cu outperformed retinol (70% vs 50% collagen responders) and Matrixyl (31.6% greater wrinkle reduction, p=0.004).
Beyond skincare, GHK-Cu shows neuroprotective effects in animal models — intranasal administration reduced amyloid plaques and improved cognition in Alzheimer’s mice.
It upregulates tumor suppressor genes (PTEN, BRCA1, TP73) and reversed 70% of overexpressed cancer genes in a metastatic colon cancer model — the opposite of the cancer concern that hangs over BPC-157 and TB-500.
Topical use has decades of safety data. Injectable protocols exist but with a much thinner evidence base.
Unlike BPC-157 and TB-500, GHK-Cu is not WADA-prohibited and is legal worldwide as a cosmetic ingredient.

A molecule your body is slowly losing

In 1973, a biochemist named Loren Pickart was working at the University of California, San Francisco, studying why liver cells from older people grew poorly in culture compared to cells from younger donors. He found that adding blood plasma from young donors to old cells restored their growth. Something in young blood was making old cells behave young.

He isolated the active factor: a tiny tripeptide — just three amino acids (glycine, histidine, lysine) — bound to a copper ion. He named it GHK-Cu and published his findings in Biochemical and Biophysical Research Communications in 1973.

What made the discovery interesting wasn’t just what GHK-Cu did. It was what happened to it over time. Pickart and later researchers measured GHK-Cu levels across age groups and found a consistent decline:

Age 20-25: ~200 ng/mL in plasma
Age 60-80: ~80 ng/mL in plasma
Decline: approximately 60%

Your body makes less of this molecule every year. And this molecule, it turns out, does a staggering number of things.

Pickart spent the next five decades studying GHK-Cu. He published 46 papers, filed 29 patents, co-founded ProCyte Corporation (which developed commercial copper peptide products in the 1990s), and later ran Skin Biology, selling GHK-Cu products directly. He died in December 2023 at age 85.

His legacy is a molecule that bridges two worlds: the massive skincare industry and the emerging science of longevity — with preliminary evidence that it may matter for brain health too.

What GHK-Cu does to your skin — the clinical evidence

Let’s start where the evidence is strongest: your skin.

Collagen and wrinkles

GHK-Cu stimulates collagen synthesis — specifically types I and III, the structural proteins that keep skin firm and smooth. It also promotes elastin production, glycosaminoglycan synthesis (the molecules that hold moisture in your skin), and the remodeling of the extracellular matrix.

The clinical numbers:

Badenhorst et al. (2016): 40 women applied GHK-Cu serum for 12 weeks. Results: 55.8% reduction in wrinkle volume (p<0.001) and 32.8% reduction in wrinkle depth (p=0.012). When compared head-to-head with Matrixyl 3000 (palmitoyl pentapeptide), GHK-Cu produced 31.6% greater wrinkle reduction (p=0.004).
Abdulghani et al. (1998): 41 women used a GHK-Cu eye cream. Result: 55% reduction in wrinkle appearance versus vitamin K cream.
Leyden et al. (2002): 71 women with facial photoaging used GHK-Cu for 12 weeks. Improvements in fine lines, skin density, and overall appearance.
GHK-Cu vs retinol vs vitamin C: In comparison studies, GHK-Cu achieved a 70% collagen response rate vs 50% for retinol and 40% for vitamin C. GHK-Cu also increased skin thickness and improved skin density more than either comparator.

Wound healing

This is where GHK-Cu’s effects get dramatic:

In controlled wound chamber studies, GHK-Cu accelerated wound closure to 538% of control values by day 22
In ischemic (blood-flow-restricted) wounds in rats, GHK-Cu reduced wound size by 64.5% compared to 28.2% in controls — with a 9-fold increase in collagen at the wound site
And here’s the striking finding: when GHK-Cu was injected in one body area (thigh muscles), it improved healing at distant body areas (ears) in rats, mice, and pigs. This suggests systemic effects from local administration.

The gene expression story — where it gets bigger than skincare

In 2010, Pickart’s group did something that changed the trajectory of GHK-Cu research. They used the Broad Institute’s Connectivity Map — a database that maps how different compounds affect gene expression across the entire human genome — to see what GHK-Cu was doing at the genetic level.

The results were extraordinary.

GHK-Cu modulated the expression of 4,309 human genes — approximately 31.2% of the human genome. Of these, 59% were upregulated (turned up) and 41% were downregulated (turned down).

This isn’t a peptide that tweaks one pathway. It’s a peptide that resets broad gene expression patterns — and the direction of the reset is consistently toward health and repair.

DNA repair genes

Gene	Change	Function
PARP3	+253%	DNA strand break repair
MRE11A	+212%	Double-strand break sensing
RAD50	+175%	DNA damage checkpoint
47 DNA repair genes total	Upregulated	—

Antioxidant and anti-inflammatory genes

Gene	Change	Function
TLE1	+762%	Anti-inflammatory transcription
IL17A	-1,018%	Pro-inflammatory cytokine (suppressed)
TNF	-115%	Tumor necrosis factor (suppressed)

Protein quality control

GHK-Cu upregulated 41 genes in the ubiquitin-proteasome system — the cellular machinery that clears damaged and misfolded proteins. This includes PARK2 (+169%), mutations in which cause early-onset Parkinson’s disease.

Insulin/IGF-1 pathway

GHK-Cu suppressed IGF1 expression by -522% and downregulated multiple insulin signaling genes. This is noteworthy because the insulin/IGF-1 pathway is the most consistently implicated pathway in aging across species — from worms to humans. Reduced IGF-1 signaling is associated with longer lifespan.

The COPD validation

This wasn’t just a theoretical exercise. Campbell et al. (2012) published in Genome Medicine that GHK-Cu’s gene expression signature was the top match for reversing the aberrant gene expression patterns seen in COPD (chronic obstructive pulmonary disease) — outperforming every pharmaceutical compound in the Connectivity Map database. This independent validation from a different research group gave the gene expression data real credibility.

The brain — early but intriguing

Two recent studies from Tucker et al. (2023) tested intranasal GHK-Cu in mouse models:

Aging mice: 8 weeks of intranasal GHK-Cu improved performance on Y-maze (p<0.05) and Box Maze (p<0.01) tests, and reduced NFL-1 (a marker of neuronal damage) (p<0.05).

Alzheimer’s mice (5xFAD model): 12 weeks of intranasal GHK-Cu reduced amyloid plaque burden (p<0.05) and MCP-1 (a neuroinflammatory chemokine) (p<0.01).

These are preprints and animal models — not clinical evidence. But they’re consistent with the broader gene expression data showing GHK-Cu upregulates neuroprotective genes (408 neuronal function genes upregulated, 230 downregulated) and acts as an HDAC inhibitor (histone deacetylase inhibition is a mechanism shared by several neuroprotective compounds).

The anti-cancer signal — the opposite of BPC-157

If you’ve read our articles on BPC-157 and TB-500, you know both carry a theoretical concern about promoting tumor growth through angiogenesis. GHK-Cu tells a different story.

Hong et al. (2010) used the Connectivity Map to analyze metastatic colon cancer gene expression. Out of 1,309 bioactive molecules tested, GHK was the single best match for reversing the cancer-associated gene expression pattern — correcting 70% of 54 overexpressed cancer genes.

GHK-Cu also upregulates key tumor suppressor genes:

PTEN — one of the most important tumor suppressors
BRCA1 — breast/ovarian cancer suppressor
ING4 — inhibitor of growth
TP73 — p53 family member (+938%)

And it upregulates 10 caspase genes — the enzymes that execute programmed cell death (apoptosis) in damaged cells.

In cell studies, GHK-Cu at 1-10 nM concentrations induced apoptosis in neuroblastoma and lymphoma cell lines via caspases 3/7 (Matalka et al.).

The caveat: This is gene expression and cell culture data — not clinical cancer treatment evidence. GHK-Cu is not a cancer drug. But the direction of the data is the opposite of BPC-157’s angiogenic concern, which is relevant context for people choosing between peptides.

The Glow Protocol — GHK-Cu meets the Wolverine Stack

The Glow Protocol combines GHK-Cu with BPC-157 and TB-500 (and sometimes KPV, an anti-inflammatory gut peptide). It was popularized primarily by Jay Campbell and has gained significant traction on TikTok (#copperpeptides has 31M+ views).

The rationale:

GHK-Cu = collagen synthesis, gene expression reset, antioxidant defense
BPC-157 = angiogenesis, localized tissue repair
TB-500 = cell migration, systemic healing, anti-inflammation
KPV = gut inflammation reduction

The evidence: Zero published studies test the combination. Individual evidence for each component varies dramatically (GHK-Cu topical data is solid; BPC-157 human data is nearly nonexistent). Until February 2026, two of the three main components (BPC-157, TB-500) were banned from US compounding pharmacies.

The Glow Protocol is a marketing concept built on theoretical complementarity. That doesn’t mean it doesn’t work — it means we don’t know if it works as a combination, and the evidence quality varies wildly between its components.

Topical vs injectable — different evidence, different risks

Topical (strong evidence)

Decades of safety data. Multiple clinical trials. Legal worldwide as a cosmetic ingredient (INCI: Copper Tripeptide-1). This is where the evidence is.

Effective concentration range: 0.5-1% for most formulations
pH requirements: 5.0-6.5 (copper peptides degrade outside this range)
Timeline to results: Most users report visible changes at 4-8 weeks
Products: The Ordinary Multi-Peptide + Copper Peptides 1% (~~$15-30), NIOD CAIS3 (~~$60+), various professional-grade serums

The “copper uglies”: A real phenomenon where overuse causes temporary skin irritation, redness, or a rough texture. Almost always caused by too much product, too frequently, especially after microneedling. It’s preventable (start slow, don’t layer with actives initially) and reversible (stop for a few days).

Injectable (thin evidence)

Injectable GHK-Cu protocols exist in the biohacking community (typically 1-2 mg subcutaneous daily for 20-30 day cycles), but the evidence base is dramatically thinner than topical:

No published human trials for injectable GHK-Cu
Safety margin appears wide: copper content per injection (~0.28 mg per 2 mg dose) is well below the 10 mg tolerable upper limit
The systemic wound healing data (thigh injection → ear healing in animals) suggests injectable delivery could produce systemic effects
But “could” is not “demonstrated in humans”

Microneedling (proceed with caution)

Microneedling with GHK-Cu is increasingly popular for deeper delivery. The science makes sense — microneedling creates channels that bypass the skin barrier. But the FDA documented 214 adverse events linked to unregulated peptide use with microneedling, and testing found 71% of gray-market microneedling vials showed bacterial contamination. If you do this, use pharmaceutical-grade product under professional supervision.

Safety

Topical: Excellent safety profile across decades of commercial use. The main risk is the “copper uglies” from overuse — uncomfortable but harmless and reversible.

Injectable: The copper content per standard dose (0.28 mg) is a fraction of the tolerable upper intake level (10 mg/day). LD50 studies show a massive safety margin (~23,000 mg for acute toxicity). The concern is not copper toxicity at therapeutic doses — it’s the lack of controlled human safety data for injectable routes.

Contraindications:

Wilson’s disease (copper metabolism disorder) — absolute contraindication
Pregnancy/breastfeeding — insufficient safety data
Active cancer — while the gene expression data is actually favorable, not enough is known to recommend use during active cancer treatment
Under 18 — no pediatric data

Not WADA-prohibited. Unlike BPC-157 and TB-500, GHK-Cu is not on the WADA banned substances list. Athletes can use topical copper peptide products without anti-doping risk.

The Pickart question — conflicts of interest

We’d be remiss not to address this. Loren Pickart was simultaneously the discoverer of GHK-Cu, the primary researcher, the patent holder, and the commercial producer. This mirrors the Sikiric/BPC-157 situation.

The important difference: GHK-Cu’s core skincare claims have been independently validated by multiple research groups (Badenhorst, Leyden, Abdulghani, Campbell). The gene expression data was generated using the Broad Institute’s Connectivity Map — an independent, publicly available database. The COPD gene reversal finding was published by an independent group in Genome Medicine.

The systemic longevity claims are less independently validated. The brain/cognitive data is from one group (Tucker) and is preclinical. So the independence picture is mixed — stronger than BPC-157’s, but not fully resolved for all applications.

What this means for you

If you’re interested in skincare: GHK-Cu has legitimate clinical evidence for wrinkle reduction, collagen synthesis, and wound healing. Start with a topical product at 0.5-1% concentration. The Ordinary’s copper peptide serum is an affordable entry point. Give it 6-8 weeks. Don’t overdo it — start every other day and build up. Don’t combine with strong actives (vitamin C, AHAs) initially.

If you’re interested in the longevity angle: The gene expression data is fascinating and has some independent validation. But gene expression changes don’t automatically translate to clinical outcomes. The gap between “modulates 4,000 genes in a favorable direction” and “makes you live longer” is enormous and unproven.

If you’re considering injectable GHK-Cu: Know that you’re working with a much thinner evidence base than topical use. The safety margin appears reasonable based on copper content calculations, but no controlled human trial has validated injectable protocols. If you proceed, work with a physician and use pharmaceutical-grade product.

If you’re considering the Glow Protocol: Read our Wolverine Stack article first. Understand that GHK-Cu is the best-evidenced component of that protocol (for topical use), while BPC-157 has essentially no human efficacy data. Don’t assume the combination is validated — it isn’t.

The unique position of GHK-Cu: It’s one of the few peptides that is simultaneously a legitimate cosmetic ingredient with clinical data, a potential longevity molecule with compelling (if preliminary) gene expression evidence, and an endogenous compound that naturally declines with age — providing a clear biological rationale for supplementation. That combination of attributes is rare in the peptide space.

Sources

Pickart L. “The human tri-peptide GHK and tissue remodeling.” J Biomater Sci Polym Ed. 2008;19(8):969-988. PMID: 18644225
Pickart L., Vasquez-Soltero J.M., Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” Biomed Res Int. 2015;2015:648108. PMID: 26236730
Pickart L., Vasquez-Soltero J.M., Margolina A. “The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline.” Brain Sciences. 2017;7(2):20. PMID: 28208599
Pickart L., Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
Pickart L. “The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging.” Oxidative Medicine and Cellular Longevity. 2012;2012:324832. PMID: 22666519
Badenhorst T. et al. “In vitro and clinical evaluation of a GHK-Cu containing cream.” Int J Cosmet Sci. 2016. Wrinkle volume reduction 55.8%, depth 32.8%, superior to Matrixyl (p=0.004).
Abdulghani A. et al. “Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin.” Skin Pharmacol Appl Skin Physiol. 1998.
Leyden J.J. et al. “Copper peptide and skin.” 2002. 71 women, 12-week facial photoaging study.
Maquart F.X. et al. “Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.” FEBS Lett. 1988;238(2):343-346. PMID: 3169264
Simeon A. et al. “Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+).” J Invest Dermatol. 2000;115(6):962-968. PMID: 11121126
Canapp S.O. et al. “The effect of topical tripeptide-copper complex on healing of ischemic open wounds.” Vet Surg. 2003;32(6):515-523. PMID: 14648529
Campbell J.D. et al. “A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK.” Genome Medicine. 2012;4(8):67. PMID: 22937864
Hong Y. et al. “GHK-Cu reversal of metastatic colon cancer gene expression.” 2010. Connectivity Map analysis, 70% of 54 overexpressed genes corrected.
Tucker et al. (2023). Intranasal GHK-Cu in aging mice. Y-maze p<0.05, Box Maze p<0.01, NFL-1 reduction p<0.05. Preprint.
Tucker et al. (2023). Intranasal GHK-Cu in 5xFAD Alzheimer’s mice. Amyloid plaque reduction p<0.05, MCP-1 reduction p<0.01. Preprint.
Matalka K.Z. et al. GHK-Cu induces apoptosis in neuroblastoma and lymphoma cells via caspases 3/7.
Philp D. et al. “Thymosin beta4 increases hair growth by activation of hair follicle stem cells.” FASEB J. 2004. (Comparative hair growth context)
Pickart L. Original discovery. Biochem Biophys Res Commun. 1973.
Sosne G. et al. Thymosin beta 4 corneal wound healing. Exp Eye Res. 2002. PMID: 11950239 (GHK-Cu comparison context)
FDA adverse event data: 214 events linked to unregulated peptide microneedling; 71% bacterial contamination in gray-market vials.
The Ordinary Copper Peptide product specifications. Concentration 1%, pH-balanced formulation.
NIOD CAIS3 product specifications. Professional-grade copper peptide serum.
GHK-Cu market data: $120M global market (2024), projected $250M by 2033. 1,016% YoY search growth.
WADA Prohibited List 2026 — GHK-Cu NOT listed.
Wilson’s disease copper metabolism — contraindication reference.
Copper tolerable upper intake level: 10 mg/day (Institute of Medicine).
Broad Institute Connectivity Map methodology. https://clue.io/
Pickart L. obituary, December 2023. 46 publications, 29 patents, founder of ProCyte Corporation and Skin Biology.